Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Sees Large Growth in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 21,400 shares, a growth of 34.6% from the August 15th total of 15,900 shares. Based on an average trading volume of 4,300 shares, the days-to-cover ratio is presently 5.0 days.

Jasper Therapeutics Stock Up 6.7 %

NASDAQ:JSPRW traded up $0.01 during mid-day trading on Monday, reaching $0.20. 5,355 shares of the company’s stock traded hands, compared to its average volume of 20,300. Jasper Therapeutics has a 12-month low of $0.04 and a 12-month high of $0.38. The company has a 50 day moving average price of $0.21 and a 200-day moving average price of $0.20.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.